ESMO 2017: Second-line treatment patterns and outcomes of metastatic bladder cancer patients in clinical practice

Madrid, Spain ( Dr. Flannery and colleagues presented their findings of second-line treatment patterns and outcomes of metastatic bladder cancer patients at ESMO 2017 poster session in Madrid, Spain. Currently, there is no universally accepted standard therapy for second-line treatment of metastatic bladder cancer. The objective of the study was to evaluate treatment patterns and outcomes of patients receiving second-line treatment for metastatic bladder cancer in real-world clinical practice.

ESMO 2017: Outcomes of patients with metastatic urothelial carcinoma with exclusive bone metastases: Focus on a special patient population

Madrid, Spain ( Patients with metastatic urothelial carcinoma with exclusive bone metastatic spread represent a rare subgroup of patients with unique clinical features. These patients deserve special consideration, as they are usually excluded from clinical trials due to the lack of measurable disease according to RECIST criteria. At today’s poster session at ESMO 2017, Dr. Andrea Necchi and colleagues focused on these patient’s access to treatment and outcomes.

ESMO 2017: Identification of genomic features underlying response of muscle-invasive bladder cancer to neoadjuvant sorafenib, gemcitabine, and cisplatin in an open-label, single-arm, phase 2 study

Madrid, Spain ( Dr. Daniele Raggi and colleagues presented results of a clinical study assessing genomic features of muscle invasive bladder cancer (MIBC) with regards to response to neoadjuvant chemotherapy at today’s ESMO 2017 poster session. Genomic analyses demonstrated that MIBC can be grouped into molecular subtypes that portend different outcomes with neoadjuvant chemotherapy (NAC).

ESMO 2017: Kidney Cancer Poster Discussion – Invited Discussant

Madrid, Spain ( Dr. Camillo Porta from Pavia, Italy provided an exceptional discussant presentation of four high-level renal cell carcinoma posters at today’s ESMO 2017 poster discussion symposium. The four posters discussed included “Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma” [1] by Dr. Toni Choueiri and colleagues, “IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma” [2] by Dr. Thomas Powles and colleagues, “Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases” [3] by Dr. Dominick Bosse and colleagues, and “Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial” [4] by Dr. Michael Staehler and colleagues.

ESMO 2017: Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: A joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration

Madrid, Spain ( Dr. Andrea Necchi and international colleagues presented results assessing adjuvant chemotherapy after radical nephroureterectomy for upper tract urothelial carcinoma (UTUC) at today’s poster session at ESMO 2017 in Madrid, Spain. In patients with UTUC the benefit of adjuvant chemotherapy after radical nephroureterectomy is debated secondary to a lack of prospective randomized trials. The objective of this study was to assess the benefit of adjuvant chemotherapy vs observation in an international study.

ESMO 2017: Avelumab treatment of metastatic urothelial carcinoma in the phase 1b JAVELIN Solid Tumor study: Updated analysis with ≥6 months of follow-up in all patients

Madrid, Spain ( Dr. Andrea B. Apolo and colleagues presented updated analysis of avelumab for patients with metastatic urothelial carcinoma at today’s ESMO 2017 meeting in Madrid, Spain. Avelumab, a human anti–PD-L1 monoclonal antibody, has shown promising efficacy and safety in patients with metastatic urothelial carcinoma. The author’s objective for this study was to report an updated analysis of avelumab treatment in two cohorts of patients from JAVELIN Solid Tumor clinical trial [1].

ESMO 2017: Immunotherapy for Urothelial Cancer – Longer Follow-up and Subgroup Analyses: Invited Discussant

Madrid, Spain ( Dr. Maria De Santis provided an excellent discussant presentation for three urothelial cancer immunotherapy posters presented at ESMO 2017 in Madrid, Spain. The posters discussed included “Pembrolizumab versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer: mature results from the phase 3 KEYNOTE-045 trial” [1] by Dr. Ronald De Wit and colleagues, “Subgroup Analyses from KEYNOTE-045: Pembrolizumab Versus Individual Investigator’s Choice of Chemotherapy (paclitaxel, docetaxel, or vinflunine) in Recurrent, Advanced Urothelial Cancer” [2] by Dr. Daniel Petrylak and colleagues, and “Atezolizumab in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma: Post-Progression Outcomes from the Phase 2 IMvigor210 Study” [3] by Dr. Andrea Necchi and colleagues.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.